ClinicalTrials.gg
RecruitingNCT05978154Updated Aug 7, 2023

Thigh Muscle Mass and Muscle Wasting in Patients in the Emergency Department

An observational study in Sepsis, Cardiac Arrest and Acute Respiratory Failure, sponsored by Korea University Ansan Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by Korea University Ansan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Sepsis with a site in Korea, Republic of — 9 open to participants now, 9 under way, none of them phase 3. Sepsis · Korea, Republic of.

Planned enrollment
3rd of 11
600 · median 245
Started
2023
with 1 other
Observational
11 of 31
7 open now
Registered
26th of 31
by date

Among the 31 studies in Sepsis with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2023, is one of 11 observational ones, and was the 26th registered.

Sepsis

2,422 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

9 of the 31 studies in Sepsis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Sepsis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate whether thigh muscle mass and muscle wasting are associated with mortality in patients who visit the emergency department. The main questions it aims to answer are:

  • Is thigh muscle mass associated with mortality in patient who visit the emergency department?
  • Does muscle wasting exist during staying in the emergency department?
  • Is muscle wasting associated with mortality in patient who visit the emergency department? Participants will be evaluated for serial thigh muscle mass using point-of-care ultrasound at the emergency department.
03

Conditions studied

  • Sepsis
  • Cardiac Arrest
  • Acute Respiratory Failure
  • Patients Who Visit Emergency Department
  • Shock
  • Trauma
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who visit the emergency department with informed consent and then who undergo point-of-care ultrasound to evaluate thigh muscle mass.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who visit the emergency department of Korea University Ansan Hospital during study period
  • patients with age within the limits
  • patients who are willing to be participate the study with
  • patients who undergo point-of-care ultrasound to evaluate thigh muscle mass

Exclusion criteria

Exclusion Criteria:

  • patients with age out of limits
  • patients who have deformities on lower leg
  • patients who is unable to maintain appropriate position to undergo point-of-care ultrasound
  • patients who decline to participate the study
  • patients who have 'do-not-resuscitate' order or are not willing to be resuscitated
  • patients of whom point-of-care ultrasound on thigh muscle mass was not performed
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Interventions

  • OtherThigh muscle mass and muscle wasting (exposure)

    Thigh muscle mass and muscle wasting (exposure variable)

06

What researchers measure

Primary outcomes

  1. 28 day mortality

    28 day mortality

    Time frame: 28 days after study enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 17 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 7, 2023
StartActual
Jul 28, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Mar 31, 2025
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05978154
Lead sponsor
Korea University Ansan Hospital
Responsible party
Ahn, Sejoong (Korea University Ansan Hospital, Korea University Ansan Hospital) — Principal investigator
First posted
Aug 7, 2023
Start date
Jul 28, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Aug 7, 2023

Study contacts

Sejoong Ahn
Contact
sejongahn@naver.com
82-10-2946-0250

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion